<DOC>
	<DOCNO>NCT02151383</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability pharmacokinetics intravenous infusion serelaxin top standard care therapy , pediatric patient acute heart failure ( AHF )</brief_summary>
	<brief_title>Pharmacokinetics &amp; Safety Serelaxin Top Standard Care Therapy Pediatric Patients With Acute Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>INCLUSION CRITERIA : Body weight ≥2.5 kg ≤120 kg Hospitalized intensive care unit stepdown unit follow : Signs symptom acute heart failure etiology Stable dose vasoactive and/or inotropic drug For nonsurgical patient echocardiographic evidence reduce ventricular function ( ejection fraction &lt; 50 % fractional shortening &lt; 28 % ) Systolic blood pressure ( SBP ) ≥25th percentile SBP age gender . EXCLUSION CRITERIA : Moderate severe leave ventricular outflow tract , mitral stenosis , aortic arch obstruction Single ventricle physiology Fixed pulmonary hypertension Blood lactate level &gt; 5 mmol/L screen Birth &lt; 36 week postconceptual age ( patient &lt; 1year old ) Confirmed clinically suspect systemic infection severe localize infection Dyspnea acute lung injury primarily due noncardiac cause Patients severe renal impairment , know significant renal disease renal replacement therapy High use inotropic and/or vasoactive agent screen Electrocardiographic abnormality Solid organ transplant recipient within 1 year transplantation one present severe organ rejection Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Acute heart failure ,</keyword>
	<keyword>RELAX−AHF−PEDIATRIC PK</keyword>
</DOC>